PB2118: PHASE 3 RANDOMIZED STUDY OF LONCASTUXIMAB TESIRINE IN COMBINATION WITH RITUXIMAB (LONCA-R) VERSUS IMMUNOCHEMOTHERAPY IN PATIENTS WITH R/R DLBCL (LOTIS-5)
M. Hamadani,
Y. Linhares,
M. D. Gandhi,
M. Chung,
H. Adamis,
D. Ungar,
C. Carlo-Stella,
E. Kingsley,
J. Depaus,
S. Snauwaert,
M. Kwiatek,
J. López-Jiménez
Affiliations
M. Hamadani
1 Cancer Center - Froedtert Hospital, Medical College of Wisconsin, Milwaukee
Y. Linhares
2 Miami Cancer Institute, Baptist Health, Miami
M. D. Gandhi
3 Virginia Cancer Specialists, Gainesville
M. Chung
4 The Oncology Institute of Hope and Innovation, Downey, United States of America
H. Adamis
5 ADC Therapeutics SA, Epalinges, Switzerland
D. Ungar
6 ADC Therapeutics America, Inc., Murray Hill, United States of America
C. Carlo-Stella
7 Humanitas Clinical and Research Center - IRCCS, Humanitas University, Milan, Italy
E. Kingsley
8 Comprehensive Cancer Centers of Nevada, Las Vegas, United States of America
J. Depaus
9 Department of Hematology, Centre Hospitalier Universitaire (CHU) Université Catholique de Louvain (UCL) Namur Site Godinne, Yvoir
